FDA sched­ules joint ad­vi­so­ry com­mit­tee meet­ing to con­sid­er first over-the-counter birth con­trol pill

The FDA has set a date to re­view what could be­come the first over-the-counter birth con­trol pill ap­proved for use in the US.

HRA Phar­ma, re­cent­ly ac­quired by Dublin-based Per­ri­go, filed back in Ju­ly to make its dai­ly prog­estin-on­ly Opill avail­able with­out a pre­scrip­tion. On Mon­day, the reg­u­la­to­ry agency sched­uled a joint meet­ing of its Non­pre­scrip­tion Drugs Ad­vi­so­ry Com­mit­tee and the Ob­stet­rics, Re­pro­duc­tive and Uro­log­ic Drugs Ad­vi­so­ry Com­mit­tee to re­view the ap­pli­ca­tion on Nov. 18 from 9 am to 5:30 pm ET.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.